Trials / Completed
CompletedNCT00225589
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 840 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 45 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin calcium |
Timeline
- Start date
- 2002-08-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2005-09-26
- Last updated
- 2010-11-19
Locations
57 sites across 8 countries: United States, Belgium, Czechia, Finland, France, Germany, Netherlands, Norway
Source: ClinicalTrials.gov record NCT00225589. Inclusion in this directory is not an endorsement.